Pipeline

Research

MedImmune has one of the largest, most robust pipelines in biopharmaceuticals – with a focus on five key areas and over 120 research projects and product candidates in our portfolio.

MedImmune currently comprises nearly 50% of AstraZeneca's pipeline, and we continue to combine our collective expertise to build a rich, diverse portfolio of small- and large-molecule compounds. This allows us to search for solutions to unmet medical needs, regardless of therapeutic modality.

Our approach to developing innovative drug candidates is to design and select candidate molecules for optimal biological properties, as well as development properties. This ensures we have the best molecules going forward.

Our pursuit of innovative drug candidates includes biosuperior products for clinically-validated targets, rather than developing biosimilars intended to copy an original molecule. Biosuperiors are designed to enhance patient value by improving upon an existing product's efficacy, safety profile, route of administration, dosing frequency, or other tangible benefit.

Download the latest version of the AstraZeneca/MedImmune development pipeline.

Filter by:

  • Oncology
  • R, I and A
  • CV/MD
  • Neuroscience
  • Infectious Diseases/Vaccines
  • Discovery
  • Pre-Clinical Development
  • Phase 1
  • Phase 2
  • Phase 3
  • Submission / Approval
Phase 1
Phase 2
Phase 3
Submission /
Approval

Phase 1

  • MEDI-565Solid Tumors
    MEDI-565 - Solid Tumors
    close

    MEDI-565 (Anti-CEA BiTE® MAb)

    For clinical trial information, visit: MEDI-565

    BiTE® is a registered trademark of Amgen Research GmbH, Munich, Germany. BiTE® technology is developed by Micromet/Amgen, Bethesda, MD and Munich, Germany

  • MEDI0639Solid Tumors
    MEDI0639 - Solid Tumors
    close

    MEDI0639 (Anti-DLL-4-MAb)

    For clinical trial information, visit: MEDI0639

    This is a partnered product.

  • MEDI0680Solid Tumors
    MEDI0680 - Solid Tumors
    close

    MEDI0680 (anti-PD-1 MAb)

    For clinical trial information, visit: MEDI0680

  • MEDI3617Solid Tumors
    MEDI3617 - Solid Tumors
    close

    MEDI3617 (Anti-ANG-2 MAb)

    For clinical trial information, visit: MEDI3617

    This is a partnered product.

  • MEDI4736Various Cancers
    MEDI4736 - Various Cancers
    close

    MEDI4736 (Anti-PD-L1 MAb)

    For clinical trial information, visit: MEDI4736

    This is a partnered product.

  • MEDI6383Solid Tumors
    MEDI6383 - Solid Tumors
    close

    MEDI6383 (OX40 agonist)

    For clinical trial information, visit: MEDI6383

    This is a partnered product.

  • MEDI6469Solid Tumors
    MEDI6469 - Solid Tumors
    close

    MEDI6469 (murine OX40 agonist)

    For clinical trial information, visit: MEDI6469

    This is a partnered product.

  • MEDI-551 + RituximabHematological Malignancies
    MEDI-551 + Rituximab - Hematological Malignancies
    close

    MEDI-551 + Rituximab (anti-CD19 MAb + anti-CD20 MAb)

    For clinical trial information, visit: MEDI-551 + Rituximab

    MedImmune-sponsored study in collaboration with Genentech.

  • MEDI-551 + MEDI0680Diffuse Large B-Cell Lymphoma
    MEDI-551 + MEDI0680 - Diffuse Large B-Cell Lymphoma
    close

    MEDI-551 + MEDI0680 (anti-CD19 MAb + anti-PD-1 MAb)

    For clinical trial information, visit: MEDI-551 + MEDI0680

    This is a partnered product.

  • MEDI4736 + MEDI0680Solid Tumors
    MEDI4736 + MEDI0680 - Solid Tumors
    close

    MEDI4736 + MEDI0680 (anti-PD-L1 MAb + anti-PD-1 MAb)

    For clinical trial information, visit: MEDI4736 + MEDI0680

    This is a partnered product.

  • MEDI4736 + MEDI6469Solid Tumors
    MEDI4736 + MEDI6469 - Solid Tumors
    close

    MEDI4736 + MEDI6469 (Anti-PD-L1 MAb + murine OX40 agonist)

    For clinical trial information, visit: MEDI4736 + MEDI6469

    This is a partnered product.

  • MEDI4736 + AZD9291Advanced EGFRm Non-Small Cell Lung Cancer
    MEDI4736 + AZD9291 - Advanced EGFRm Non-Small Cell Lung Cancer
    close

    MEDI4736 + AZD9291 (anti-PD-L1 MAb + EGFR tyrosine kinase inhibitor)

    For clinical trial information, visit: MEDI4736 + AZD9291

    This is a partnered product.

  • MEDI4736 + AZD9291Non-Small Cell Lung Cancer
    MEDI4736 + AZD9291 - Non-Small Cell Lung Cancer
    close

    MEDI4736 + AZD9291 (anti-PD-L1 MAb + EGFR tyrosine kinase inhibitor)

    For clinical trial information, visit: MEDI4736 + AZD9291

    This is a partnered product.

  • MEDI4736 + Dabrafenib + TrametinibMelanoma
    MEDI4736 + Dabrafenib + Trametinib - Melanoma
    close

    MEDI4736 + Dabrafenib + Trametinib (Anti-PD-L1 MAb + BRAF inhibitor + MEK inhibitor)

    For clinical trial information, visit: MEDI4736 + dabrafenib + trametinib

    MedImmune-sponsored study in collaboration with GSK.

  • MEDI4736 + IRESSANon-Small Cell Lung Cancer
    MEDI4736 + IRESSA - Non-Small Cell Lung Cancer
    close

    MEDI4736 + IRESSA (anti-PD-L1 MAb + EGFR inhibitor)

    For clinical trial information, visit: MEDI4736 + IRESSA

    This is a partnered product.

  • MEDI4736 + TremelimumabSolid Tumors
    MEDI4736 + Tremelimumab - Solid Tumors
    close

    MEDI4736 + Tremelimumab (anti-PD-L1 MAb + anti-CTLA-4 MAb)

    For clinical trial information, visit: MEDI4736 + Tremelimumab

    This is a partnered product.

  • MEDI6469 + TremelimumabSolid Tumors
    MEDI6469 + Tremelimumab - Solid Tumors
    close

    MEDI6469 + Tremelimumab (murine OX40 agonist + anti-CTLA-4 MAb)

    For clinical trial information, visit: MEDI6469 + Tremelimumab

    This is a partnered product.

  • MEDI-551Multiple Sclerosis
    MEDI-551 - Multiple Sclerosis
    close

    MEDI-551 (anti-CD19 MAb)

    For clinical trial information, visit: MEDI-551

    This is a partnered product.

  • MEDI4920Primary Sjögren's Syndrome
    MEDI4920 - Primary Sjögren's Syndrome
    close

    MEDI4920 (anti-CD40L-Tn3 fusion protein)

    For clinical trial information, visit: MEDI4920

  • MEDI5872Systemic Lupus Erythematosus
    MEDI5872 - Systemic Lupus Erythematosus
    close

    MEDI5872 (anti-B7RP1 MAb)

    For clinical trial information, visit: MEDI5872

    This is a partnered product.

  • MEDI6012 Acute Coronary Syndrome
    MEDI6012 - Acute Coronary Syndrome
    close

    MEDI6012 (LCAT)

    For clinical trial information, visit: MEDI6012

  • MEDI8111Trauma / Bleeding
    MEDI8111 - Trauma / Bleeding
    close

    MEDI8111 (Rh-Factor II)

    For clinical trial information, visit: MEDI8111

  • MEDI-550Pandemic Influenza Prophylaxis
    MEDI-550 - Pandemic Influenza Prophylaxis
    close

    MEDI-550 (pandemic influenza virus vaccine)

  • MEDI-559RSV Prophylaxis
    MEDI-559 - RSV Prophylaxis
    close

    MEDI-559 (pediatric RSV vaccine)

    For clinical trial information, visit: MEDI-559

  • MEDI3902Pseudomonas
    MEDI3902 - Pseudomonas
    close

    MEDI3902 (anti-Psl/PcrV)

    For clinical trial information, visit: MEDI3902

  • MEDI7510Prevention of RSV in Older Adults
    MEDI7510 - Prevention of RSV in Older Adults
    close

    MEDI7510 (RSV sF+GLA-SE)

    For clinical trial information, visit: MEDI7510

  • MEDI8897Passive RSV Prophylaxis
    MEDI8897 - Passive RSV Prophylaxis
    close

    MEDI8897 (anti-RSV MAb-YTE)

    For clinical trial information, visit: MEDI8897

    This is a partnered product.

  • MEDI1814Alzheimer's Disease
    MEDI1814 - Alzheimer's Disease
    close

    MEDI1814 (anti-amyloid beta MAb)

    For clinical trial information, visit: MEDI1814

Phase 2

  • MEDI-551Chronic Lymphocytic Leukemia
    MEDI-551 - Chronic Lymphocytic Leukemia
    close

    MEDI-551 (Anti-CD19 MAb)

    For clinical trial information, visit: MEDI-551

    This is a partnered product.

  • MEDI-551Diffuse Large B-Cell Lymphoma
    MEDI-551 - Diffuse Large B-Cell Lymphoma
    close

    MEDI-551 (Anti-CD19 MAb)

    For clinical trial information, visit: MEDI-551

    This is a partnered product.

  • MEDI-573Metastatic Breast Cancer
    MEDI-573 - Metastatic Breast Cancer
    close

    MEDI-573 (Anti-IGF MAb)

    For clinical trial information, visit: MEDI-573

    This is a partnered product.

  • MEDI4736Solid Tumors
    MEDI4736 - Solid Tumors
    close

    MEDI4736 (Anti-PD-L1 MAb)

    For clinical trial information, visit: MEDI4736

    This is a partnered product.

  • Moxetumomab PasudotoxPediatric Acute Lymphoblastic Leukemia
    Moxetumomab Pasudotox - Pediatric Acute Lymphoblastic Leukemia
    close

    Moxetumomab Pasudotox (anti-CD22 recombinant immunotoxin)

    For clinical trial information, visit: Moxetumomab Pasudotox

    This is a partnered product.

  • MEDI2070Crohn's Disease
    MEDI2070 - Crohn's Disease
    close

    MEDI2070 (anti-IL-23 MAb)

    For clinical trial information, visit: MEDI2070

    MEDI2070 is being jointly developed in collaboration with Amgen.

  • MEDI7183Crohn's Disease
    MEDI7183 - Crohn's Disease
    close

    MEDI7183 (anti-A4b7 MAb)

    For clinical trial information, visit: MEDI7183

    MEDI7183 is being jointly developed in collaboration with Amgen.

  • MEDI7183Ulcerative Colitis
    MEDI7183 - Ulcerative Colitis
    close

    MEDI7183 (anti-A4b7 MAb)

    For clinical trial information, visit: MEDI7183

    MEDI7183 is being jointly developed in collaboration with Amgen.

  • MEDI9929Asthma
    MEDI9929 - Asthma
    close

    MEDI9929 (anti-TSLP MAb)

    For clinical trial information, visit: MEDI9929

    MEDI9929 is being jointly developed in collaboration with Amgen.

  • AnifrolumabSystemic Lupus Erythematosus
    Anifrolumab - Systemic Lupus Erythematosus
    close

    Anifrolumab (anti-IFN-alphaR MAb)

    For clinical trial Information, visit: Anifrolumab

    This is a partnered product.

  • Brodalumab Asthma
    Brodalumab - Asthma
    close

    Brodalumab (anti-IL-17R MAb)

    For clinical trial information, visit: Brodalumab

    Brodalumab is being jointly developed in collaboration with Amgen.

  • Mavrilimumab Rheumatoid Arthritis
    Mavrilimumab - Rheumatoid Arthritis
    close

    Mavrilimumab (anti-GM-CSFR-MAb)

    For clinical trial information, visit: Mavrilimumab

    This is a partnered product.

  • SifalimumabSystemic Lupus Erythematosus
    Sifalimumab - Systemic Lupus Erythematosus
    close

    Sifalimumab (anti-IFN-alpha MAb)

    For clinical trial information, visit: Sifalimumab

    This is a partnered product.

  • TralokinumabIdiopathic Pulmonary Fibrosis
    Tralokinumab - Idiopathic Pulmonary Fibrosis
    close

    Tralokinumab (anti-IL-13 MAb)

    For clinical trial information, visit: Tralokinumab

  • MEDI4893S. aureus Pneumonia
    MEDI4893 - S. aureus Pneumonia
    close

    MEDI4893 (MAb binding to S. aureus toxin)

    For clinical trial information, visit: MEDI4893

Phase 3

  • MEDI4736Stage III Non-Small Cell Lung Cancer
    MEDI4736 - Stage III Non-Small Cell Lung Cancer
    close

    MEDI4736 (Anti-PD-L1 MAb)

    For clinical trial information, visit: MEDI4736

    This is a partnered product.

  • MEDI47363rd Line Non-Small Cell Lung Cancer
    MEDI4736 - 3rd Line Non-Small Cell Lung Cancer
    close

    MEDI4736 (Anti-PD-L1 MAb)

    For clinical trial information, visit: MEDI4736

    This is a partnered product.

    Registrational Phase II/III study

     

  • Moxetumomab Pasudotox Hairy Cell Leukemia
    Moxetumomab Pasudotox - Hairy Cell Leukemia
    close

    Moxetumomab Pasudotox (anti-CD22 recombinant immunotoxin)

    For clinical trial information, visit: Moxetumomab Pasudotox

    This is a partnered product.

  • TremelimumabMesothelioma
    Tremelimumab - Mesothelioma
    close

    Tremelimumab (Anti-CTLA-4 MAb)

    For clinical trial information, visit: Tremelimumab

  • BenralizumabCOPD
    Benralizumab - COPD
    close

    Benralizumab (anti-IL-5R MAb)

    For clinical trial information, visit: Benralizumab

    Benralizumab is in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd. Under the exclusive license agreement, Kyowa Hakko Kirin/BioWa have exclusive development and commercialization rights for benralizumab in Japan and certain countries in Asia. AstraZeneca has exclusive rights for benralizumab in all other countries including the US and Europe.

  • Benralizumab Severe Asthma
    Benralizumab - Severe Asthma
    close

    Benralizumab (anti-IL-5R alpha MAb)

    For clinical trial information, visit: Benralizumab

    Benralizumab is in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd. Under the exclusive license agreement, Kyowa Hakko Kirin/BioWa have exclusive development and commercialization rights for benralizumab in Japan and certain countries in Asia. AstraZeneca has exclusive rights for benralizumab in all other countries including the US and Europe.

  • Brodalumab Psoriasis
    Brodalumab - Psoriasis
    close

    Brodalumab (anti-IL17R MAb)

    For clinical trial information, visit: Brodalumab

    Brodalumab is being jointly developed in collaboration with Amgen.

  • Brodalumab Psoriatic Arthritis
    Brodalumab - Psoriatic Arthritis
    close

    Brodalumab (anti-IL17R MAb)

    For clinical trial information, visit: Brodalumab

    Brodalumab is being jointly developed in collaboration with Amgen.

  • Tralokinumab Severe Asthma
    Tralokinumab - Severe Asthma
    close

    Tralokinumab (anti-IL-13 MAb)

    For clinical trial information, visit: Tralokinumab

Submission / Approval

  • Q-LAIV Flu VaccineInfluenza
    Q-LAIV Flu Vaccine - Influenza
    close

    MEDI-3250

    On February 29, 2012, FluMist Quadrivalent (Influenza Vaccine Live, Intranasal) was approved by the FDA.

    For clinical trial information, visit: Quad Flu Vaccine

Last updated: February 05, 2015